Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)

Naruto Taira, Kosuke Kashiwabara, Junji Tsurutani, Masahiro Kitada, Masato Takahashi, Hiroaki Kato, Yuichiro Kikawa, Eiko Sakata, Yoichi Naito, Yoshie Hasegawa, Tsuyoshi Saito, Tsutomu Iwasa, Tsutomu Takashima, Tomohiko Aihara, Hirofumi Mukai, Fumikata Hara

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original publication of the article, the Table 2 was published incorrectly with missing values. The corrected Table 2 is given in this correction. The original article has been corrected. (Table presented.).

Original languageEnglish
JournalBreast Cancer
DOIs
Publication statusAccepted/In press - 2021

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)'. Together they form a unique fingerprint.

Cite this